Staar Surgical
This article was originally published in The Gray Sheet
Executive Summary
Board authorizes share buyback program under which the Monrovia, California-based ophthalmic surgery products firm will repurchase up to one million shares of its common stock over a two-year period. Shares in Staar have been trading for around $10 per share. The buyback program reflects Staar's "confidence" about its "long term prospects," the company says, adding that the share repurchases will benefit stockholders by reducing the number of Staar shares. The repurchases "will be made in the public market or through private sales" and "when or if such repurchases are deemed advisable." Staar currently has 13 mil. shares of common stock outstanding. The firm recently reported third quarter net income of $1.7 mil. -- representing an increase of 178% from last year's third quarter -- on revenues of $6.9 mil., up 46.8%
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.